Biosimulation refers to computer aided simulation of biological processes and
systems, an integral part of systems biology used in drug discovery and
development. This report will analyze the potential of biosimulation in drug
discovery and development. Biosimulation is used across the drug discovery and
development program (such as target identification, target validation, lead
discovery, lead optimization, preclinical and clinical test).
The global biosimulation market was valued at $432.0 million in 2011 and is
expected to reach $1.2 billion by 2017, at a CAGR of 18.50%. Biosimulation in
preclinical and clinical stages contributed maximum share (60%) to the global
biosimulation market in 2011.
The major driving factor for this market is the cost and time spent on drug
discovery and development programs and failure of drug candidates in the late
development stages. Pharmaceutical companies around the globe spent around $68
billion in 2011 in drug discovery and development programs, many of the drug
discovery and development programs fail in the late stages of the clinical
trials, wasting all the years of efforts and money. There is a need for
predictive technology which would outlay the outcome of a drug candidate in
the discovery stages; biosimulation is one such technology which can bring
down the cost on drug discovery and development programmes by focusing on
promising lead drug candidates and experiments.
North America is the biggest market for biosimulation followed by Europe.
North America, which is the largest drug market in the world contributes one
third for the global biosimulation market. Europe is the fastest growing
market for biosimulation the growth is attributed to the efforts of regulatory
bodies in promoting new technologies in drug discovery and development. Asian
market is still considered to be in development stages because of non
availability of skilled workforce and infrastructure in place.
We have also profiled leading players of this industry with their recent
developments and other strategic industry activities. These include: Accelrys
(U.S.), Schrodinger (U.S.), Certara (U.S.), Simulation plus (U.S.), Rhenovia
(France), ACD/Labs (Canada), CCG (Canada), LeadScope (U.S.), Entelos (U.S.),
Genedata (Switzerland), Physiomics (U.K.), Insilico biotechnology (Germany),
Insilico biosciences (U.S.), Archimedes (U.S.), Compugen (Israel).
Scope of the Report
This research report categorizes global biosimulation market for drug
discovery and development on the basis of application and geography;
forecasting volume and analyzing trends in the region by application.
On the basis of Applications: The biosimulation market is segmented on the
basis of its application in drug discovery and development processes such as:
Target identification and validation, lead discovery, optimization,
preclinical and clinical trials. Each application is further described in
detail in the report with volume and revenue forecasted for each application.
On the basis of Geography: North America, Europe, Asia and ROW.
Biosimulation Market Share, By Geography
Source: Secondary source, Expert interview,
Markets and Markets Analysis
Table of Contents
Table of Contents
1. INTRODUCTION
1.1. KEY TAKE AWAYS
1.2. REPORT DESCRIPTION
1.3. MARKETS COVERED
1.4. STAKEHOLDERS
1.5. RESEARCH METHODOLOGY
1.5.1. MARKET SIZE
1.5.2. MARKET SHARE
1.5.3. KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4. KEY DATA POINTS FROM PRIMARY SOURCES
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
3.1. INTRODUCTION
3.2. MARKET SEGMENTATION
3.3. MARKET DYNAMICS
3.3.1. DRIVERS
3.3.1.1. Need for new tools in drug discovery process
3.3.1.2. Increased spending on healthcare
3.3.1.3. Cost attributed to the traditional drug discovery process
3.3.1.4. Failure of drug candidates in the late development stages
3.3.1.5. Improved computational power
3.3.1.6. Improved modelling & simulation tools
3.3.2. RESTRAINTS
3.3.2.1. Unproven predictive methodology
3.3.2.2. Risk of Potential safe drug failing in biosimulation
3.3.2.3. Lack of standardization
3.3.2.4. Limited knowledge of biological systems & process
3.3.3. CHALLENGES
3.3.3.1. Increasing accuracy in prediction
3.3.3.2. Increasing collaboration/partnership among vendors &
pharmaceutical companies
3.3.3.3. Integration of other technologies for better predictive models
Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 - 2017) published by Markets and Markets in October 22, 2012. This report consists of 123 Pages and the price starts from US $ 4650.
